A Phase 3 interventional study of Abraxane (Induction) and Carboplatin (Induction) in Squamous Cell Carcinoma, Non-Small-Cell Lung, sponsored by Celgene. Completed at 119 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-17.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 330 studies in Carcinoma, Squamous Cell with a site in United States — 68 open to participants now, 99 under way, 6 of them phase 3. Carcinoma, Squamous Cell · United States.
Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, this one is the 22nd largest by enrollment of the 280 interventional ones that give a count, is one of 17 that started in 2014, is one of 24 in phase 3, and was the 126th registered.
628 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.
Browse Carcinoma, Squamous Cell studies →68 of the 330 studies in Carcinoma, Squamous Cell with a site in United States are open now. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Rockefeller University · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
330 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 108 · Phase 2 138 · Phase 3 28 · Phase 4 4
First in 1994; this study’s year is marked. 17 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 427 is above the median of 45 across 478 interventional studies indexed under Carcinoma, Squamous Cell.
Median enrollment 37 across the 280 interventional studies, 64 across the 45 observational. Of the 203 that completed or were terminated, 94 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 330 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
Bristol-Myers Squibb has 3 studies filed under Carcinoma, Squamous Cell — fewer than ten, so there is no comparison to draw.
31 of the studies in Carcinoma, Squamous Cell with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07931664The Center for Clinical and Cosmetic ResearchEvaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | 2026-11 |
| NCT06615635Alpha Tau Medical LTD.Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients | 2026-12 |
| NCT05863052University of OklahomaAnalyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | 2026-12-31 |
| NCT05366166UNC Lineberger Comprehensive Cancer CenterPembrolizumab Plus Olaparib in LA-HNSCC | 2027-01-21 |
Add all 31 to your calendar (.ics) → With an account.
Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Maintenance treatment of advanced stage squamous cell NSCLC.
Phase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable disease (SD) with nab-paclitaxel plus carboplatin as induction in subjects with stage IIIB/IV squamous cell NSCLC.
Subjects who discontinued treatment from the maintenance part for any reason other than withdrawal of consent, lost to follow-up, or death, were entered into a Follow-up period that had a visit 28 days after progression or discontinuation.
Those who entered Follow-up without progression continued with follow-up scans according to standard of care (SOC) until documentation of progression of disease. Additionally, subjects were followed for OS by phone approximately every 90 days for a minimum of 18 months, for up to approximately 5 years after the last subject was randomized.
The sponsor used 15 Sep 2017 as the database cut-off date.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able to adhere to the study visit schedule and other protocol requirements
Disease Specific
For Maintenance part of the study, subjects must have received at least one dose of nab-paclitaxel in each of the 4 cycles during Induction
Pregnancy
Females of [defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:
Male subjects must:
c. agree to complete abstinence from heterosexual contact or use a condom during sexual contact with a female of child bearing potential while receiving study medication and within 6 months after last dose of study medication, even if he has undergone a successful vasectomy.
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment into the Induction and Maintenance parts of the study (except if specified at study entry only):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.
Drug: Abraxane (Induction) · Drug: Carboplatin (Induction) · Drug: Abraxane (Maintenance) · Other: Best Supportive Care (Maintenance)
Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.
Drug: Abraxane (Induction) · Drug: Carboplatin (Induction) · Other: Best Supportive Care (Maintenance)
100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
Also known as: nab-paclitaxel
6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
Also known as: nab-paclitaxel
6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance
Progression-free survival is defined as the time in months from the date of randomization to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by computerized axial tomography \[CT scan\], not including symptomatic deterioration) or death (any cause) on or prior to 01 Aug 2019. RECIST 1.1 Definition: - Complete response (CR) -disappearance of all target lesions; - Partial response (PR) -at least a 30% decrease in the sum of diameters of target lesions from baseline - Stable disease (SD) -neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase of lesions to qualify for progressive disease (PD) - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir, and/or the appearance of new lesions.
Time frame: From the date of randomization to the date of disease progression or death of any cause; up to data cut off date of 15 September 2017; up to 27.6 months
Kaplan-Meier Estimate of Overall Survival (OS) From Randomization Into Maintenance
Overall survival was defined as the duration in months between randomization and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off (01 August 2019 whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive.
Time frame: From the date of randomization to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) Over Entire Study
Overall response was defined as the percentage of participants with a confirmed assessment of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and confirmed in no less than 28 days. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \< 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline.
Time frame: Day 1 of treatment in the induction period and subsequent anticancer therapy, death or discontinuation up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
Kaplan-Meier Estimate of Progression-Free Survival (PFS) Over Entire Study
PFS was defined as the time in months from Day 1 of treatment for the Induction part to the date of disease progression according to RECIST 1.1 criteria (documented by CT-scan, not including symptomatic deterioration) or death (any cause) on or prior to 01 August 2019, whichever occurred earlier. RECIST 1.1 Definition: - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progression.
Time frame: Between Day 1 of the Induction Part through to the date of disease progression or death; up to 01 August 2019; the maximum treatment duration was 234.1 weeks for entire study
Kaplan-Meier Estimate of Overall Survival (OS) Over Entire Study
Overall survival was defined as the time in months from Day 1 of treatment for the Induction part to death from any cause. Subjects who were alive at the time of analysis had their OS censored at the date or last contact of 01 August 2019, whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive.
Time frame: Between Day 1 of treatment in the Induction Part to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) In Maintenance Beyond the Response in Induction
Overall response in the maintenance period was defined as the percentage of participants who showed an improvement in best overall response from stable disease (SD) or partial response (PR) during Induction to a Complete Response (CR) or PR during Maintenance according to RECIST 1.1 criteria and confirmed in no less than 28 days. Evaluation takes as reference the lesion measurement or status at the last tumor assessment before randomization to Maintenance. The 95% CI was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. - Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease.
Time frame: For the induction period the maximum treatment was 19 weeks for the maintenance period the maximum treatment was 150 weeks.
Percentage of Participants Who Achieved Disease Control (Disease Control Rate) by Investigator Assessment During Induction and Over the Entire Study
Disease control rate was defined as the percentage of participants who had radiologic CR, PR or SD for \>= 6 weeks according to RECIST 1.1 criteria as determined by the investigator. Only participants with a confirmed CR/PR are included in this summary. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. RECIST 1.1 Definition: - CR- disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \< 10 mm. - PR- at least a 30% decrease in the sum of diameters of target lesions from baseline; - SD- neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The 95% CI was calculated using Clopper-Pearson method.
Time frame: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 induction through maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
Time to Confirmed Response During Induction and Over the Entire Study
Time to confirmed complete or partial response (CR/PR) is defined as the time from day 1 of treatment in Induction to the first occurrence of confirmed CR/PR. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. Only participants with a confirmed CR or PR are included in this summary.
Time frame: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 Induction through Maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
Kaplan-Meier Estimate for Duration of Response Over the Entire Study
Duration of overall response was measured from the time criteria were first met for CR/PR until the first date the recurrent or progressive disease (PD) was radiologically documented. Participants who did not have PD after the response were censored on the date of last tumor assessment. If a participant died before PD, the participant was censored on the date of death.
Time frame: Between Day 1 of the Induction Period through to the date of disease progression or death; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study.
Participants With Treatment-Emergent Adverse Events (TEAEs) in the Induction Period
TEAE in the Induction part is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and on or before the day of randomization for subjects who entered into the Maintenance part, or, for subjects who did not enter into the Maintenance part, before the treatment discontinuation date plus 28 days or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate Grade, 3 = Severe Grade, 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator.
Time frame: Day 1 of Induction up to Week 23 (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance)
Participants With Treatment-Emergent Adverse Events (TEAEs) Over the Entire Study
TEAE over entire study is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and before the treatment discontinuation date plus 28 days, or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator.
Time frame: From Day 1 up to 01 August 2019; (maximum treatment length plus 28 days); the maximum treatment duration was 234.1 weeks for entire study
The study was conducted at 87 sites in Germany, Italy, Spain, the United Kingdom and the United States.
| Milestone | All Participants - Induction | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) |
|---|---|---|---|
| Started | 427 | 0 | 0 |
| Received study drug | 420 | 0 | 0 |
| Completed | 202 | 0 | 0 |
| Not completed | 225 | 0 | 0 |
| Withdrew: Never treated | 7 | 0 | 0 |
| Withdrew: Progressive disease | 77 | 0 | 0 |
| Withdrew: Adverse event | 51 | 0 | 0 |
| Withdrew: Withdrawal by subject | 22 | 0 | 0 |
| Withdrew: Death | 21 | 0 | 0 |
| Withdrew: Symptomatic deterioration | 16 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 12 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Miscellaneous | 14 | 0 | 0 |
| Withdrew: Induction treatment ongoing | 4 | 0 | 0 |
| Milestone | All Participants - Induction | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) |
|---|---|---|---|
| Started | 0 | 136 | 66 |
| Completed | 0 | 12 | 6 |
| Not completed | 0 | 124 | 60 |
| Withdrew: Death | 0 | 3 | 2 |
| Withdrew: Adverse event | 0 | 21 | 1 |
| Withdrew: Progressive disease | 0 | 84 | 47 |
| Withdrew: Symptomatic deterioration | 0 | 4 | 1 |
| Withdrew: Withdrawal by subject | 0 | 6 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Other | 0 | 6 | 3 |
| Milestone | All Participants - Induction | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) |
|---|---|---|---|
| Started | 0 | 117 | 55 |
| Completed | 0 | 38 | 9 |
| Not completed | 0 | 79 | 46 |
| Withdrew: Death | 0 | 78 | 45 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
Progression-free survival is defined as the time in months from the date of randomization to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by computerized axial tomography \[CT scan\], not including symptomatic deterioration) or death (any cause) on or prior to 01 Aug 2019. RECIST 1.1 Definition: - Complete response (CR) -disappearance of all target lesions; - Partial response (PR) -at least a 30% decrease in the sum of diameters of target lesions from baseline - Stable disease (SD) -neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase of lesions to qualify for progressive disease (PD) - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir, and/or the appearance of new lesions.
| months | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) |
|---|---|---|
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance | 3.12 (2.73 to 4.60) | 2.60 (1.64 to 3.45) |
Overall survival was defined as the duration in months between randomization and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off (01 August 2019 whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive.
| months | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) |
|---|---|---|
| Kaplan-Meier Estimate of Overall Survival (OS) From Randomization Into Maintenance | 17.61 (13.86 to 21.09) | 12.16 (7.56 to 18.99) |
Overall response was defined as the percentage of participants with a confirmed assessment of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and confirmed in no less than 28 days. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \< 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline.
| percentage of participants | Nab-Paclitaxel + BSC: Induction + Maintenance | BSC: Induction + Maintenance |
|---|---|---|
| Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) Over Entire Study | 69.1 (60.6 to 76.8) | 57.6 (44.8 to 69.7) |
PFS was defined as the time in months from Day 1 of treatment for the Induction part to the date of disease progression according to RECIST 1.1 criteria (documented by CT-scan, not including symptomatic deterioration) or death (any cause) on or prior to 01 August 2019, whichever occurred earlier. RECIST 1.1 Definition: - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progression.
| months | Nab-Paclitaxel + BSC: Induction + Maintenance | BSC: Induction + Maintenance |
|---|---|---|
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) Over Entire Study | 6.47 (5.65 to 7.79) | 5.55 (4.96 to 6.67) |
Overall survival was defined as the time in months from Day 1 of treatment for the Induction part to death from any cause. Subjects who were alive at the time of analysis had their OS censored at the date or last contact of 01 August 2019, whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive.
| months | Nab-Paclitaxel + BSC: Induction + Maintenance | BSC: Induction + Maintenance |
|---|---|---|
| Kaplan-Meier Estimate of Overall Survival (OS) Over Entire Study | 20.57 (17.05 to 24.05) | 15.05 (10.81 to 22.14) |
Overall response in the maintenance period was defined as the percentage of participants who showed an improvement in best overall response from stable disease (SD) or partial response (PR) during Induction to a Complete Response (CR) or PR during Maintenance according to RECIST 1.1 criteria and confirmed in no less than 28 days. Evaluation takes as reference the lesion measurement or status at the last tumor assessment before randomization to Maintenance. The 95% CI was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. - Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease.
| percentage of participants | Nab-Paclitaxel + BSC: Induction + Maintenance | BSC: Induction + Maintenance |
|---|---|---|
| Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) In Maintenance Beyond the Response in Induction | 9.6 (5.2 to 15.8) | 3.0 (0.4 to 10.5) |
Disease control rate was defined as the percentage of participants who had radiologic CR, PR or SD for \>= 6 weeks according to RECIST 1.1 criteria as determined by the investigator. Only participants with a confirmed CR/PR are included in this summary. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. RECIST 1.1 Definition: - CR- disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \< 10 mm. - PR- at least a 30% decrease in the sum of diameters of target lesions from baseline; - SD- neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The 95% CI was calculated using Clopper-Pearson method.
| percentage of participants | All Participants - Induction | Nab-Paclitaxel + BSC: Induction + Maintenance | BSC: Induction + Maintenance |
|---|---|---|---|
| Percentage of Participants Who Achieved Disease Control (Disease Control Rate) by Investigator Assessment During Induction and Over the Entire Study | 47.9 (43.0 to 52.8) | 99.3 (96.0 to 100.0) | 100.0 (94.6 to 100.0) |
Time to confirmed complete or partial response (CR/PR) is defined as the time from day 1 of treatment in Induction to the first occurrence of confirmed CR/PR. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. Only participants with a confirmed CR or PR are included in this summary.
| months | All Participants - Induction | Nab-Paclitaxel + BSC: Induction + Maintenance | BSC: Induction + Maintenance |
|---|---|---|---|
| Time to Confirmed Response During Induction and Over the Entire Study | 1.446 (1.15 to 4.60) | 1.478 (1.15 to 8.51) | 1.413 (1.18 to 4.21) |
Duration of overall response was measured from the time criteria were first met for CR/PR until the first date the recurrent or progressive disease (PD) was radiologically documented. Participants who did not have PD after the response were censored on the date of last tumor assessment. If a participant died before PD, the participant was censored on the date of death.
| months | Nab-Paclitaxel + BSC: Induction + Maintenance | BSC: Induction + Maintenance |
|---|---|---|
| Kaplan-Meier Estimate for Duration of Response Over the Entire Study | 5.95 (4.60 to 7.06) | 4.60 (3.68 to 5.49) |
TEAE in the Induction part is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and on or before the day of randomization for subjects who entered into the Maintenance part, or, for subjects who did not enter into the Maintenance part, before the treatment discontinuation date plus 28 days or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate Grade, 3 = Severe Grade, 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator.
| Participants | All Participants - Induction | TEAE Specific to Nab-Paclitaxel | TEAE Specific to Carboplatin |
|---|---|---|---|
| TEAE | 419 | NA | NA |
| Serious TEAE | 177 | NA | NA |
| Severity Grade 3/4 TEAE | 337 | NA | NA |
| Severity Grade 3 or higher TEAE | 340 | NA | NA |
| Treatment-related (trt-related) TEAE | 408 | 407 | 394 |
| Trt-related serious TEAE | 82 | 80 | 73 |
| TEAE-study drug dose reduced or interrupted | 341 | 340 | 291 |
| Trt-related TEAE-dose reduced or interrupted | 301 | 292 | 236 |
| TEAE-study drug withdrawn | 55 | 55 | 53 |
| Trt-related TEAE-study drug withdrawn | 35 | 34 | 29 |
| TEAE-outcome of death | 32 | NA | NA |
| Trt-related TEAE-outcome of death | 7 | 7 | 6 |
TEAE over entire study is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and before the treatment discontinuation date plus 28 days, or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator.
| Participants | Nab-Paclitaxel + BSC: Induction + Maintenance | Nab-Paclitaxel + BSC: TEAE Specific to Nab-Paclitaxel | Nab-Paclitaxel + BSC: TEAE Specific to Carboplatin | Nab-Paclitaxel + BSC: TEAE Specific to BSC | BSC: Induction + Maintenance | BSC: TEAE Specific to Nab-Paclitaxel | BSC: TEAE Specific to Carboplatin | BSC: TEAE Specific to BSC |
|---|---|---|---|---|---|---|---|---|
| TEAE | 130 | NA | NA | NA | 62 | NA | NA | NA |
| Serious TEAE | 54 | NA | NA | NA | 21 | NA | NA | NA |
| Severity Grade 3/4 TEAE | 108 | NA | NA | NA | 48 | NA | NA | NA |
| Severity Grade 3 or higher TEAE | 109 | NA | NA | NA | 48 | NA | NA | NA |
| Treatment-related (trt-related) TEAE | 129 | 129 | 123 | 18 | 61 | 61 | 58 | 1 |
| Trt-related serious TEAE | 22 | 22 | 16 | 1 | 8 | 8 | 7 | 0 |
| TEAE-study drug dose reduced or interrupted | 115 | 113 | 95 | 17 | 52 | 52 | 45 | 1 |
| Trt-related TEAE-dose reduced or interrupted | 107 | 104 | 85 | 0 | 45 | 45 | 37 | 0 |
| TEAE-study drug withdrawn | 22 | 22 | 1 | 20 | 0 | 1 | 1 | 0 |
| Trt-related TEAE- study drug withdrawn | 18 | 18 | 1 | 2 | 1 | 0 | 0 | 0 |
| TEAE-outcome of death | 4 | NA | NA | NA | 2 | NA | NA | NA |
| Trt-related TEAE-outcome of death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over 1. All Participants - Induction: Day 1 up to 23 weeks (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance) 2. Nab-Paclitaxel + Best Supportive Care (BSC): Randomization into Maintenance up to 154 weeks (maximum treatment in Maintenance plus 4 weeks) 3. Best Supportive Care (BSC): Randomization into Maintenance up to 120 weeks (maximum treatment in Maintenance plus 4 weeks) TEAEs are reported up to the data cut off date of 01 August 2019.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants - Induction | 80/420 (19%) | 177/420 (42.1%) | 417/420 (99.3%) |
| Nab-Paclitaxel + Best Supportive Care (Maintenance) | 82/130 (63.1%) | 32/130 (24.6%) | 122/130 (93.8%) |
| Best Supportive Care (Maintenance) | 48/62 (77.4%) | 13/62 (21%) | 45/62 (72.6%) |
| Event | All Participants - Induction | Nab-Paclitaxel + Best Supportive Care (Maintenance) | Best Supportive Care (Maintenance) |
|---|---|---|---|
| PneumoniaInfections and infestations | 24/420 | 4/130 | 3/62 |
| AnaemiaBlood and lymphatic system disorders | 17/420 | 3/130 | 0/62 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 15/420 | 0/130 | 0/62 |
| DehydrationMetabolism and nutrition disorders | 14/420 | 1/130 | 0/62 |
| General physical health deteriorationGeneral disorders | 4/420 | 0/130 | 2/62 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 7/420 | 0/130 | 2/62 |
| NeutropeniaBlood and lymphatic system disorders | 12/420 | 0/130 | 0/62 |
| DiarrhoeaGastrointestinal disorders | 11/420 | 1/130 | 1/62 |
| HypotensionVascular disorders | 11/420 | 0/130 | 0/62 |
| AstheniaGeneral disorders | 6/420 | 3/130 | 0/62 |
| Event | All Participants - Induction | Nab-Paclitaxel + Best Supportive Care (Maintenance) | Best Supportive Care (Maintenance) |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 256/420 | 24/130 | 6/62 |
| NeutropeniaBlood and lymphatic system disorders | 225/420 | 14/130 | 0/62 |
| NauseaGastrointestinal disorders | 191/420 | 16/130 | 2/62 |
| Peripheral sensory neuropathyNervous system disorders | 152/420 | 56/130 | 6/62 |
| FatigueGeneral disorders | 175/420 | 24/130 | 0/62 |
| ThrombocytopeniaBlood and lymphatic system disorders | 163/420 | 9/130 | 2/62 |
| DiarrhoeaGastrointestinal disorders | 158/420 | 18/130 | 4/62 |
| ConstipationGastrointestinal disorders | 130/420 | 14/130 | 0/62 |
| AlopeciaSkin and subcutaneous tissue disorders | 105/420 | 6/130 | 2/62 |
| Decreased appetiteMetabolism and nutrition disorders | 101/420 | 17/130 | 3/62 |
Induction includes participants who were enrolled and treated however, baseline characteristics (BLC) for non-randomised participants is not displayed. The total number represents the ITT population in the maintenance phase.
| Age, Continuous(years) | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) | Total |
|---|---|---|---|
| Mean | 67.1 ± 9.02 | 66.8 ± 8.06 | 67.0 ± 8.70 |
| Age, Customized(Participants) | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) | Total |
|---|---|---|---|
| <65 years | 48 | 27 | 75 |
| >=65 years | 88 | 39 | 127 |
| <70 years | 79 | 41 | 120 |
| >=70 years | 57 | 25 | 82 |
| <75 years | 110 | 55 | 165 |
| >=75 years | 26 | 11 | 37 |
| Sex: Female, Male(Participants) | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) | Total |
|---|---|---|---|
| Female | 49 | 23 | 72 |
| Male | 87 | 43 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 8 |
| Not Hispanic or Latino | 132 | 61 | 193 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Black or African American | 9 | 2 | 11 |
| White | 125 | 62 | 187 |
| Other | 0 | 2 | 2 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(Participants) | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) | Total |
|---|---|---|---|
| 0=fully active, no restriction | 41 | 19 | 60 |
| 1=fully ambulatory; restricted strenuous activity | 95 | 47 | 142 |
| >=2=ambulatory/self care; no work or worse | 0 | 0 | 0 |
| Overall Tumor Response at End of Induction(Participants) | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) | Total |
|---|---|---|---|
| Complete response | 1 | 2 | 3 |
| Partial response | 92 | 42 | 134 |
| Stable disease | 41 | 21 | 62 |
| Progressive disease | 2 | 0 | 2 |
| Not evaluable | 0 | 1 | 1 |
| Confirmed Histology(Participants) | Nab-Paclitaxel + Best Supportive Care (BSC) | Best Supportive Care (BSC) | Total |
|---|---|---|---|
| Squamous cell carcinoma | 136 | 66 | 202 |
| Squamous cell carcinoma not confirmed | 0 | 0 | 0 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 119 sites across 5 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2014 to primary completion in Sep 2017, 43 months.
Results were first posted in Dec 2018, 1 year 2 months after primary completion.
Of 21 phase 3 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 91. This study's 43 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel